Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high ...

Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of ...

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025 20 May 2025. MOUNT LAUREL, N.J. ... Nucleic Acids Research, Physical Review, ...

Y-mAbs Therapeutics, Inc. has announced the presentation of its GD2-SADA pretargeted radioimmunotherapy as part of a trial in progress at the Advances in Neuroblastoma Research Meeting in ...

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025 Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational ...